A Real World Data of Ocrelizumab in Multiple Sclerosis

被引：0
|
作者：
Beckmann, Y.
Uzunkopru, C.
机构：
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1240
引用
收藏
页码：671 / 671
页数：1
相关论文
共 50 条
  • [21] Safety and effectiveness of ocrelizumab in multiple sclerosis: a real-world study from spain
    Sempere, A.
    Berenguer-Ruiz, L.
    Burgos-San Jose, A.
    Aragones, M.
    Navarro-Lopez, M. D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 553 - 553
  • [22] Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario
    Lorefice, Lorena
    Mellino, Paolo
    Frau, Jessica
    Coghe, Giancarlo
    Fenu, Giuseppe
    Cocco, Eleonora
    NEUROLOGICAL SCIENCES, 2024, 45 (08) : 3951 - 3959
  • [23] Real-world comparison of Rituximab and Ocrelizumab effectiveness in Multiple Sclerosis: a multicenter study
    Smolik, Krzysztof
    Camilli, Federico
    Del Prete, Claudia
    Foschi, Matteo
    Surcinelli, Andrea
    Curti, Erica
    Tsantes, Elena
    Ferri, Caterina
    Guareschi, Angelica
    Bazzurri, Veronica
    Montepietra, Sara
    Simone, Anna Maria
    Mancinelli, Luca
    Lugaresi, Alessandra
    Falzone, Francesca
    Piscaglia, Maria Grazia
    Granella, Franco
    Baldi, Eleonora
    Pesci, Ilaria
    Immovilli, Paolo
    Santangelo, Mario
    Cardi, Martina
    Fiore, Alessia
    De Napoli, Giulia
    Vitetta, Francesca
    Ferraro, Diana
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 373 - 374
  • [24] Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric study
    Skoric, Magdalena Krbot
    Kes, Vanja Basic
    Grbic, Nevena
    Lazibat, Ines
    Pavelin, Sanda
    Zubonja, Tea Mirosevic
    Komso, Milica
    Piskac, Spomenka Kidemet
    Abicic, Ana
    Piskac, Dominik
    Adamec, Ivan
    Barun, Barbara
    Gabelic, Tereza
    Habek, Mario
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
  • [25] Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
    Lanzillo, Roberta
    Carotenuto, Antonio
    Signoriello, Elisabetta
    Iodice, Rosa
    Miele, Giuseppina
    Bisecco, Alvino
    Maniscalco, Giorgia Teresa
    Sinisi, Leonardo
    Romano, Felice
    Di Gregorio, Maria
    Lavorgna, Luigi
    Trojsi, Francesca
    Moccia, Marcello
    Fratta, Mario
    Capasso, Nicola
    Dubbioso, Raffaele
    Petracca, Maria
    Spiezia, Antonio Luca
    Gallo, Antonio
    Petruzzo, Martina
    De Angelis, Marcello
    Bonavita, Simona
    Lus, Giacomo
    Tedeschi, Gioacchino
    Morra, Vincenzo Brescia
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (08)
  • [26] A real-world data study of coronavirus-2019 disease severity in patients with multiple sclerosis treated with ocrelizumab
    Dillon, P.
    Waqar, A.
    Roumpanis, S.
    Martinec, M.
    Muros-Le Rouzic, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 103 - 104
  • [27] Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers
    Diem, L.
    Ovchinnikov, A.
    Friedli, C.
    Hammer, H.
    Kamber, N.
    Chan, A.
    Salmen, A.
    Findling, O.
    Hoepner, R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 86
  • [28] Two-year real-world experience with ocrelizumab in the treatment of patients with multiple sclerosis
    Vollmer, B.
    Ijadi, N.
    Declusin, A.
    Nair, K.
    Sillau, S.
    Corboy, J.
    Vollmer, T.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 595 - 596
  • [29] Findings from a large monocentric real-world experience of Ocrelizumab use in Multiple Sclerosis
    Mellino, Paolo
    Pilotto, Silvy
    Frau, Jessica
    Carmagnini, Daniele
    Coghe, Giancarlo
    Cocco, Eleonora
    Lorefice, Lorena
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 613 - 614
  • [30] Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients
    Prockl, Victoria
    Nickel, Florian T.
    Utz, Kathrin S.
    Froehlich, Kilian
    Engelhorn, Tobias
    Hilz, Max-Josef
    Lee, De-Hyung
    Linker, Ralf A.
    Huhn, Konstantin
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 415
12345